2. Zimmermann A, Bernuit D, Gerlinger C, et al. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Gezondheid van de vrouw. 2012;12(1):6.
3. Whiteman MK, Hillis SD, Jamieson DJ, et al. Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol. 2008;198(1):34.e1-34.e7.
4. Vilos GA, Allaire C, Laberge PY, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can. 2015;37(2):157-181.
5. Bulun SE. Baarmoederfibromen. N Engl J Med. 2013;369(14):1344-1355.
6. Ishikawa H, Ishi K, Serna VA, et al. Progesteron is essentieel voor onderhoud en groei van uterus leiomyoma. Endocrinology. 2010;151(6):2433-2442.
7. Ross RK, Pike MC, Vessey MP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives . Br Med J (Clin Res Ed). 1986;293(6543):359-362.
8. Ryan GL, Syrop CH, Van Voorhis BJ. Role, epidemiology, and natural history of benign uterine mass lesions. Clin Obstet Gynecol. 2005;48(2):312-324.
9. Chiaffarino F, Parazzini F, La Vecchia C, et al. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol. 1999;106(8):857–860.
10. Stewart EA, Nicholson WK, Bradley L, et al. The burden of uterine fibroids for African-American women: results of a national survey. J Womens Health (Larchmt). 2013;22(10):807–816.
11. Munro MG, Storz K, Abbott JA, et al. Practice guidelines for the management of hysteroscopic distending media. J Minim Invasive Gynecol. 2013;20(2):137-148.
12. Drayer SM, Catherino WH. Prevalentie, morbiditeit en huidige medische behandeling van uterus leiomyomen. Int J Gynaecol Obstet. 2015;131(2):117–122.
13. Bukulmez O, Doody KJ. Klinische kenmerken van myomen. Obstet Gynecol Clin North Am. 2006;33(1):69-84.
14. Carranza-Mamane B, Havelock J, Hemmings R, et al. The management of uterine fibroids in women with otherwise unexplained infertility. J Obstet Gynaecol Can. 2015;37(3):277-288.
15. Metwally M, Cheong YC, Horne AW. Chirurgische behandeling van myomen voor subfertiliteit. Cochrane Database Syst Rev. 2012;(11):CD003857.
16. Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril. 2009;91(4):1215–1223.
17. De Vivo A, Mancuso A, Giacobbe A, et al. Uterine myomas during pregnancy: a longitudinal sonographic study. Echografie Obstet Gynecol. 2011;37(3):361-365.
18. Hammoud AO, Asaad R, Berman J, et al. Volumeverandering van baarmoedermyomen tijdens de zwangerschap: groeien myomen echt? J Minim Invasive Gynecol. 2006;13(5):386-390.
19. Stout MJ, Odibo AO, Graseck AS, et al. Leiomyomas at routine second-trimester ultrasound examination and adverse obstetric outcomes. Obstet Gynecol. 2010;116(5):1056–1063.
20. Klatsky PC, Tran ND, Caughey AB, et al. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. Am J Obstet Gynecol. 2008;198(4):357–366.
21. Knight J, Falcone T. Weefselextractie door morcellatie: een klinisch dilemma. J Minim Invasive Gynecol. 2014;21(3):319-320.
22. ACOG praktijkbulletin. Alternatieven voor hysterectomie bij de behandeling van leiomyomen. Obstet Gynecol. 2008;112(2 pt 1):387-400.
23. Practice Committee of American Society for Reproductive Medicine; Society of Reproductive Surgeons. Myomen en reproductieve functie. Fertil Steril. 2008;90(5 suppl):S125-S130.
24. Singh SS, Belland L. Contemporary management of uterine fibroids: focus on emerging medical treatments . Curr Med Res Opin. 2015;31(1):1-12.
25. Dueholm M, Lundorf E, Hansen ES, et al. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol. 2002;186(3):409–415.
26. Cicinelli E, Romano F, Anastasio PS, et al. Transabdominale sonohysterografie, transvaginale sonografie, en hysteroscopie in de evaluatie van submucous myomas. Obstet Gynecol. 1995;85(1):42-47.
27. Thomassin-Naggara I, Dechoux S, Bonneau C, et al. How to differentiate benign from malignant myometrial tumors using MR imaging. Eur Radiol. 2013;23(8):2306–2314.
28. Bonneau C, Thomassin-Naggara I, Dechoux S, et al. Waarde van ultra-sonografie en magnetische resonantie beeldvorming voor de karakterisering van uteriene mesenchymale tumoren. Acta Obstet Gynecol Scand. 2014;93(3):261-268.
29. Varelas FK, Papanicolaou AN, Vavatsi-Christaki N, et al. Het effect van anastrazol op symptomatische uteriene leiomyomata. Obstet Gynecol. 2007;110(3):643–649.
30. Wright JD, Tergas AI, Burke WM, et al. Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation. JAMA. 2014;312(12):1253–1255.
31. Fleischer AC, James AE Jr, Millis JB, et al. Differential diagnosis of pelvic masses by gray scale sonography. AJR Am J Roentgenol. 1978;131(3):469–476.
32. Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy. BJOG. 2002;109(10):1097–1108.
33. Sayed GH, Zakherah MS, El-Nashar SA, et al. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet. 2011;112(2):126–130.
34. Lethaby A, Duckitt K, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2013;(1):CD000400.
35. Tristan M, Orozco LJ, Steed A, et al. Mifepriston voor uterusmyomen. Cochrane Database Syst Rev. 2012;(8):CD007687.
36. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristalacetaat versus placebo voor behandeling van vleesbomen vóór operatie. N Engl J Med. 2012;366(5):409–420.
37. Lethaby A, Farquhar C, Cooke I. Antifibrinolytica voor hevig menstrueel bloedverlies. Cochrane Database Syst Rev. 2000;(4):CD000249.
38. Lukes AS, Moore KA, Muse KN, et al. Tranexaminezuur behandeling voor hevig menstrueel bloedverlies. Obstet Gynecol. 2010;116(4):865–875.
39. Aarts JW, Nieboer TE, Johnson N, et al. Chirurgische benadering van hysterectomie voor goedaardige gynaecologische aandoeningen. Cochrane Database Syst Rev. 2015;(8):CD003677.
40. Stewart EA, Gostout B, Rabinovici J, et al. Duurzame verlichting van symptomen van leiomyomen door het gebruik van gerichte ultrageluidchirurgie. Obstet Gynecol. 2007;110(2 pt 1):279-287.
41. Bhave Chittawar P, Franik S, et al. Minimaal invasieve chirurgische technieken versus open myomectomie voor uterusmyomen. Cochrane Database Syst Rev. 2014;(10):CD004638.
42. Gupta JK, Sinha A, Lumsden MA, et al. Uterusarterie embolisatie voor symptomatische uterusmyomen. Cochrane Database Syst Rev. 2014;(12):CD005073.
43. Sesti F, Cosi V, Calonzi F, et al. Gerandomiseerde vergelijking van totale laparoscopische, laparoscopisch geassisteerde vaginale en vaginale hysterectomieën voor myomateuze uteri. Arch Gynecol Obstet. 2014;290(3):485–491.
44. Hwang JL, Seow KM, Tsai YL, et al. Vergelijkende studie van vaginale, laparoscopisch geassisteerde vaginale en abdominale hysterectomieën voor uterus myomen groter dan 6 cm in diameter of uterus met een gewicht van ten minste 450 g. Acta Obstet Gynecol Scand. 2002;81(12):1132–1138.
45. Zapata LB, Whiteman MK, Tepper NK, et al. Intrauterine device use among women with uterine fibroids. Anticonceptie. 2010;82(1):41-55.
46. Venkatachalam S, Bagratee JS, Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera). J Obstet Gynaecol. 2004;24(7):798-800.
47. Verspyck E, Marpeau L, Lucas C. Leuprorelin depot 3.75 mg versus lynestrenol in de preoperatieve behandeling van symptomatische baarmoedermyomen. Eur J Obstet Gynecol Reprod Biol. 2000;89(1):7-13.
48. Ichigo S, Takagi H, Matsunami K, et al. Gunstige effecten van dienogest op het volume van baarmoedermyomen. Arch Gynecol Obstet. 2011;284(3):667–670.
49. Ip PP, Lam KW, Cheung CL, et al. Tranexaminezuur-geassocieerde necrose en intralesionale trombose van uteriene leiomyomen. Am J Surg Pathol. 2007;31(8):1215–1224.
50. Peitsidis P, Koukoulomati A. Tranexaminezuur voor de behandeling van baarmoederfibroomtumoren. World J Clin Cases. 2014;2(12):893-898.
51. Milsom I, Andersson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991;164(3):879–883.
52. Carbonell Esteve JL, Acosta R, Heredia B, et al. Mifepristone for the treatment of uterine leiomyomas. Obstet Gynecol. 2008;112(5):1029–1036.
53. Hilário SG, Bozzini N, Borsari R, et al. Werking van aromataseremmer voor de behandeling van uterus leiomyoma bij perimenopauzale patiënten. Fertil Steril. 2009;91(1):240-243.
54. Gurates B, Parmaksiz C, Kilic G, et al. Behandeling van symptomatisch uterus leiomyoom met letrozol. Reprod Biomed Online. 2008;17(4):569-574.
55. Song H, Lu D, Navaratnam K, et al. Aromataseremmers voor uterusmyomen. Cochrane Database Syst Rev. 2013;(10):CD009505.
56. Sadan O, Ginath S, Sofer D, et al. The role of tamoxifen in the treatment of symptomatic uterine leiomyomata-a pilot study. Eur J Obstet Gynecol Reprod Biol. 2001;96(2):183-186.
57. Deng L, Wu T, Chen XY, et al. Selective oestrogeen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev. 2012;(10):CD005287.
58. U.S. Food and Drug Administration. Bijgewerkt: laparoscopische uterus power morcellation bij hysterectomie en myomectomie: FDAsafety communication. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm424443.htm. Geraadpleegd op 20 januari 2016.
59. American College of Obstetricians and Gynecologists (Amerikaans College van Verloskundigen en Gynaecologen). Power morcellation en occulte maligniteit in gynaecologische chirurgie. http://www.acog.org/Resources-And-Publications/Task-Force-and-Work-Group-Reports/Power-Morcellation-and-Occult-Malignancy-in-Gynecologic-Surgery. Accessed January 20, 2016.
60. Bogani G, Cliby WA, Aletti GD. Impact van morcellatie op overlevingsuitkomsten van patiënten met onverwacht uterus leiomyosarcoom. Gynecol Oncol. 2015;137(1):167–172.
61. Carlson KJ, Miller BA, Fowler FJ Jr. The Maine women’s health study: I. uitkomsten van hysterectomie. Obstet Gynecol. 1994;83(4):556-565.
62. Camanni M, Bonino L, Delpiano EM, et al. Hysteroscopic management of large symptomatic submucous uterine myomas. J Minim Invasive Gynecol. 2010;17(1):59-65.
63. Goodwin SC, Spies JB. Uterine fibroid embolization. N Engl J Med. 2009;361(7):690–697.
64. Hirst A, Dutton S, Wu O, et al. A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids. Health Technol Assess. 2008;12(5):1-248.
65. Taran FA, Tempany CM, Regan L, et al.; MRgFUS Group. Magnetic resonance-guided focused ultrasound (MRgFUS) vergeleken met abdominale hysterectomie voor de behandeling van uteriene leiomyomen. Echografie Obstet Gynecol. 2009;34(5):572-578.
66. Quinn SD, Vedelago J, Gedroyc W, et al. Safety and five-year re-intervention following magnetic resonance-guided focused ultrasound (MRgFUS) for uterine fibroids. Eur J Obstet Gynecol Reprod Biol. 2014;182:247-251.
67. Rabinovici J, David M, Fukunishi H, et al.; MRgFUS Study Group. Zwangerschapsuitkomst na magnetische resonantie-geleide gerichte ultrasone chirurgie (MRgFUS) voor conservatieve behandeling van uterusmyomen. Fertil Steril. 2010;93(1):199-209.
68. Evans P, Brunsell S. Baarmoederfibroomtumoren: diagnose en behandeling. Am Fam Physician. 2007;75(10):1503–1508.